Home » Stocks » OptiNose

OptiNose, Inc. (OPTN)

Stock Price: $6.45 USD -0.65 (-9.15%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 296.09M
Revenue (ttm) 37.22M
Net Income (ttm) -110.04M
Shares Out 45.91M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $6.45
Previous Close $7.10
Change ($) -0.65
Change (%) -9.15%
Day's Open 7.06
Day's Range 6.03 - 7.10
Day's Volume 859,742
52-Week Range 3.28 - 11.66

More Stats

Market Cap 296.09M
Enterprise Value 252.28M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.91M
Float 29.41M
EPS (basic) -2.55
EPS (diluted) -2.56
FCF / Share -1.95
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.83M
Short Ratio 22.99
Short % of Float 24.63%
Beta 0.92
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.96
PB Ratio 8.19
Revenue 37.22M
Operating Income -94.72M
Net Income -110.04M
Free Cash Flow -89.55M
Net Cash 43.82M
Net Cash / Share 0.95
Gross Margin 78.83%
Operating Margin -254.52%
Profit Margin -295.70%
FCF Margin -240.61%
ROA -32.25%
ROE -172.63%
ROIC -133.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$17.67*
(173.95% upside)
Low
13.0
Current: 6.45
High
20.0
Target: 17.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue34.637.07-47.500.09
Revenue Growth390.18%--55782.35%-
Gross Profit29.345.48-47.500.09
Operating Income-95.60-100-48.5325.32-28.08
Net Income-110-107-48.9022.61-28.31
Shares Outstanding41.8839.7711.004.054.05
Earnings Per Share-2.63-2.68-5.630.32-9.97
Operating Cash Flow-90.82-91.82-35.6821.72-28.71
Capital Expenditures-0.56-1.69-2.41-0.22-0.08
Free Cash Flow-91.37-93.51-38.0921.51-28.79
Cash & Equivalents14720123536.8015.20
Total Debt74.5372.5071.8615.2614.48
Net Cash / Debt72.6112816321.540.72
Assets17321724141.5516.01
Liabilities11198.3886.6424.5822.34
Book Value61.58119154-151-161
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OptiNose, Inc.
Country United States
Employees 221
CEO Peter Kaighn Miller

Stock Information

Ticker Symbol OPTN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: OPTN
IPO Date October 13, 2017

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.